New study tests rectal gel as a discreet HIV prevention option

NCT ID NCT06560684

Ongoing Prevention Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jan 16, 2026 · Last updated May 16, 2026 · Updated 14 times

Summary

This study tests two ways to prevent HIV: a rectal gel and oral pills, both taken only when needed. About 150 men will try each method for 8 weeks to see which is safer, easier to use, and preferred. The goal is to offer more choices for HIV prevention.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TENOFOVIR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Alabama CRS (Site ID# 31788)

Birmingham, Alabama, 35222, United States
Chapel Hill CRS (3201)

Chapel Hill, North Carolina, 27599-7215, United States
Fenway Health (FH) CRS

Boston, Massachusetts, 02215-4302, United States
Hope Clinic CRS

Lawrenceville, Georgia, 30046, United States
Johns Hopkins University CRS

Baltimore, Maryland, 21287, United States
UCLA CARE Center CRS

Los Angeles, California, 90035, United States
University of Pittsburgh CRS

Pittsburgh, Pennsylvania, 15213, United States
Weill Cornell Chelsea CRS

New York, New York, 10011, United States

Conditions

Explore the condition pages connected to this study.

TENOFOVIR